Stock Quote
PDL BioPharma, Inc. (PDLI.O) (Nasdaq)
$7.86
2:56pm EST
-0.51%
$7.90
$7.94
2,302,202
$8.15
$7.85
$9.32
$5.20
0.69
2,721,407
PDLI.O
More News
| Press Releases
| Key Developments
| Name | Current Position | Compensation |
|---|---|---|
| McLaughlin, John | President, Chief Executive Officer, Director | 181,208 |
| Larson, Christine | Chief Financial Officer, Vice President | 24,613 |
| Wilson, Karen | Vice President - Finance, Principal Accounting Officer | -- |
Profile
PDL BioPharma, Inc. (PDL) is engaged in the business of management of its antibody humanization patents and royalty assets, which consist of the Company’s Queen et al. patents and license agreements with several biotechnology and pharmaceutical companies. The Company receives royalties based on... Full Description
Company Address
PDL BioPharma, Inc.
34801 Campus Drive
Fremont CA 94555
P: +1510.5741400
F: +1510.5741500
34801 Campus Drive
Fremont CA 94555
P: +1510.5741400
F: +1510.5741500
Analyst Research
Performance of Key Competitors
| Company | Price | Change |
|---|---|---|
| Baxter International Inc. | $54.76 | +0.43 |
| Hospira, Inc. | $47.43 | +0.55 |
| Genentech, Inc. | -- | -- |
| PDLI.O | Industry | |
|---|---|---|
| P/E(TTM) | 5.95 | 6.90 |
| P/S(TTM) | 2.88 | 1.54 |
| ROI(TTM) | 66.87 | 6.18 |
| ROE(TTM) | -- | 9.32 |
| Consensus Recommendation | Hold |
|---|---|
| EPS Est. (Current Period) | 0.29 |
| EPS Est. (Current Year) | 1.17 |
| Total Revenue | $71.45M |
| Net Income | $46.41M |
| EPS | $0.29 |
